Baseline covariates and survival outcomes from the OAK clinical trial, a Phase III study comparing atezolizumab (MPDL3280A) with docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Patients were matched to those in tumor_data using baseline SLD, treatment arm, and best overall response.
Format
A tibble with one row per patient and 12 columns:
- id
Patient identifier (factor), matched to tumor_data
- arm
Treatment arm (factor):
"Docetaxel"or"MPDL3280A"- ecog
ECOG performance status at baseline (factor):
0or1- age
Age at baseline in years (numeric)
- race
Patient race (factor)
- sex
Patient sex (factor):
"F"or"M"- sld
Baseline sum of longest diameters of target lesions in mm (numeric)
- response
Best overall response (factor):
"CR","PR","SD","PD", or"NE"- pfs_time
Progression-free survival time in years (numeric)
- pfs_event
Progression-free survival event indicator (logical):
TRUE= event observed- os_time
Overall survival time in years (numeric)
- os_event
Overall survival event indicator (logical):
TRUE= death observed
Source
Supplementary Table 8 from: Rittmeyer A, Barlesi F, Waterkamp D, et al. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet 389(10066): 255–265. https://doi.org/10.1038/s41591-018-0134-3
Data preparation code adapted from: Sabanes Bove D and Mercier F. https://rconis.github.io/tgi-os-training/